Technical Analysis for CADL - Candel Therapeutics, Inc.

Grade Last Price % Change Price Change
F 5.04 21.89% 0.91
CADL closed up 21.89 percent on Friday, November 22, 2024, on 6.97 times normal volume.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
New Uptrend Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion 21.89%
Oversold Stochastic Weakness 21.89%

   Recent Intraday Alerts

Alert Time
Possible Pocket Pivot about 17 hours ago
Up 2 ATRs about 18 hours ago
Rose Above 20 DMA about 18 hours ago
60 Minute Opening Range Breakout about 18 hours ago
20 DMA Resistance about 18 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Candel Therapeutics, Inc. Description

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Drugs Immunotherapy Surgery Tumor Cancer Immunotherapy Chemotherapy Radiation Pancreatic Cancer Metastases

Is CADL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 14.3
52 Week Low 0.77
Average Volume 331,062
200-Day Moving Average 5.68
50-Day Moving Average 5.82
20-Day Moving Average 4.76
10-Day Moving Average 4.26
Average True Range 0.44
RSI (14) 52.15
ADX 28.82
+DI 29.33
-DI 19.69
Chandelier Exit (Long, 3 ATRs) 4.74
Chandelier Exit (Short, 3 ATRs) 5.10
Upper Bollinger Bands 5.91
Lower Bollinger Band 3.61
Percent B (%b) 0.62
BandWidth 48.26
MACD Line -0.43
MACD Signal Line -0.47
MACD Histogram 0.0381
Fundamentals Value
Market Cap 145.76 Million
Num Shares 28.9 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -4.58
Price-to-Sales 1334.04
Price-to-Book 1.59
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.11
Resistance 3 (R3) 7.06 6.31 6.77
Resistance 2 (R2) 6.31 5.79 6.34 6.65
Resistance 1 (R1) 5.68 5.46 6.00 5.73 6.53
Pivot Point 4.93 4.93 5.09 4.96 4.93
Support 1 (S1) 4.30 4.41 4.62 4.35 3.55
Support 2 (S2) 3.55 4.08 3.58 3.43
Support 3 (S3) 2.92 3.55 3.32
Support 4 (S4) 2.97